Topics: Corporate, Evotec, Yumanity Therapeutics, Parkinson's disease, INDiGO, IND Enabling Read More

Evotec leverages INDiGO platform to accelerate the development of Carna's programme CB-1763 through to IND filing IND-filing envisaged for first half of 2019 INDiGO, a key value-driving component of Evotec's EVT Execute business segment, accelerates early drug candidates into the clinic by reducing ...

Topics: Corporate, INDiGO, Carna Biosciences, Blood cancer Read More

Petra Pharma Corporation to harness Evotec's INDiGO platform to accelerate its lead programme (Petra-01 for oncology indications) through IND filing Evotec eligible to receive success-based milestones and research funding Evotec's INDiGO, a key value-driving component of its EVT Execute business ...

Topics: Corporate, INDiGO Read More

INDiGO® is the market leading integrated drug development solution that accelerates drug candidate delivery from candidate selection through to IND submission in typically less than 52 weeks.

Topics: Corporate, INDiGO Read More